Zuzanna Michalska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zuzanna Michalska has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Stańczyk
Clinical Hospital of the Ministry of Internal Affairs and Administration with the Warmia-Mazury Oncology Centre in Olsztyn, Poland
9 shared publications - Amelia KęDziora
University of Warmia and Mazury in Olsztyn, Poland
9 shared publications - Anna ŁęCzycka
Independent Public Health Care Facility of the Ministry of Internal Affairs and Administration in Gdańsk, Poland
9 shared publications - Iga Suchta
District Hospital in Proszowice, Poland
9 shared publications - Izabela Zuzanna Stranz
Ludwik Rydygier Provincial Hospital in Toruń, Toruń, Poland
9 shared publications - Joanna Strzelczyk
Nicolaus Copernicus Provincial Multispecialty Center for Oncology and Traumatology in Łódź, Poland
9 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Institute of Rural Health in Environmental Medicine
- Vol. 29 (2) , 55-61
Impact of climate change on the epidemiology of tick-borne encephalitis in Europe – a narrative review
Introduction and objective: Tick-borne encephalitis (TBE) is an important viral infection caused by Flavivirus, primarily transmitted by Ixodes ricinus ticks. Its incidence and geographic range are increasing across Europe. The aim of the review is to assess currently available evidence on...
- 22 September 2026
- Published by Institute of Rural Health in Environmental Medicine
- Vol. 29 (2) , 55-61
Open AccessImpact of climate change on the epidemiology of tick-borne encephalitis in Europe – a narrative review
Introduction and objective: Tick-borne encephalitis (TBE) is an important viral infection caused by Flavivirus, primarily transmitted by Ixodes ricinus ticks. Its incidence and geographic range are increasing across Europe. The aim of the review is to assess currently available evidence on...
- Open Access
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
INDOCYANINE GREEN FLUORESCENCE IN ONCOLOGIC SURGERY: A CRITICAL REVIEW OF SENTINEL LYMPH NODE MAPPING AND TUMOR MARGIN ASSESSMENT
Objective: To critically evaluate current evidence regarding the clinical utility, effectiveness, and limitations of indocyanine green (ICG) fluorescence imaging in oncologic surgery, with particular emphasis on sentinel lymph node mapping and tumor margin assessment. Methods: A narrative literature review was conducted using the PubMed database. Studies published between 2013 and 2025 were analyzed, including clinical studies, randomized trials, systematic reviews, meta-analyses, consensus statements, and methodological papers addressing oncologic applications of ICG fluorescence imaging. Results: Strong evidence supports the use of ICG fluorescence imaging in sentinel lymph node mapping across colorectal, gastric, breast, and gynecologic cancers. The technique improves visualization of lymphatic pathways and facilitates intraoperative navigation. Evidence regarding tumor margin assessment remains heterogeneous, with diagnostic performance limited by the non-specific accumulation of ICG and variability among imaging protocols. Conclusions: ICG fluorescence imaging is an effective and increasingly valuable tool in oncologic surgery, particularly for sentinel lymph node mapping. However, its role in tumor margin assessment remains less established. Further standardization and development of tumor-specific fluorescence agents are required to optimize clinical applications.
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Open AccessINDOCYANINE GREEN FLUORESCENCE IN ONCOLOGIC SURGERY: A CRITICAL REVIEW OF SENTINEL LYMPH NODE MAPPING AND TUMOR MARGIN ASSESSMENT
Objective: To critically evaluate current evidence regarding the clinical utility, effectiveness, and limitations of indocyanine green (ICG) fluorescence imaging in oncologic surgery, with particular emphasis on sentinel lymph node mapping and tumor margin assessment. Methods: A narrative literature review was conducted using the PubMed database. Studies published between 2013 and 2025 were analyzed, including clinical studies, randomized trials, systematic reviews, meta-analyses, consensus statements, and methodological papers addressing oncologic applications of ICG fluorescence imaging. Results: Strong evidence supports the use of ICG fluorescence imaging in sentinel lymph node mapping across colorectal, gastric, breast, and gynecologic cancers. The technique improves visualization of lymphatic pathways and facilitates intraoperative navigation. Evidence regarding tumor margin assessment remains heterogeneous, with diagnostic performance limited by the non-specific accumulation of ICG and variability among imaging protocols. Conclusions: ICG fluorescence imaging is an effective and increasingly valuable tool in oncologic surgery, particularly for sentinel lymph node mapping. However, its role in tumor margin assessment remains less established. Further standardization and development of tumor-specific fluorescence agents are required to optimize clinical applications.
- Open Access
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
BURNOUT AND MORAL INJURY AMONG RESIDENTS AND EARLY-CAREER PHYSICIANS: AN INTERNATIONAL REVIEW OF OBSERVATIONAL EVIDENCE
Background. Burnout among healthcare workers is now recognised as a public-health concern in its own right, with residents and early-career physicians disproportionately affected. The construct of moral injury — distress arising when clinicians cannot act in accordance with their professional values because of system-level constraints — has been proposed as a complement to the classical burnout framework. Aim. To synthesise contemporary observational evidence on the epidemiology of burnout, its principal risk factors, and the role of moral injury among residents and early-career physicians, with particular attention to the Polish context. Methods. A literature review of observational studies published between 2009 and 2025 was conducted in PubMed, Scopus, and Web of Science, following the STROBE statement for reporting. Because of methodological heterogeneity, no quantitative meta-analysis was attempted; findings were integrated through qualitative narrative synthesis. Results. Burnout prevalence in this population ranged from approximately 30% to over 60%, depending on geography, specialty, and measurement instrument [11,12]. Dominant risk factors were organisational: excessive workload, administrative load, restricted professional autonomy, and impaired work–life balance. Personal attributes rarely operated as independent predictors but appeared to modify risk. Moral injury emerged as a meaningful complement to burnout, capturing the value-conflict dimension that burnout scales tend to miss [8,9]. Conclusions. Burnout and moral injury together pose a serious challenge to healthcare systems. Prevention strategies that focus exclusively on individual resilience are unlikely to succeed; the evidence points instead to structural and organisational reform [31].
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Open AccessBURNOUT AND MORAL INJURY AMONG RESIDENTS AND EARLY-CAREER PHYSICIANS: AN INTERNATIONAL REVIEW OF OBSERVATIONAL EVIDENCE
Background. Burnout among healthcare workers is now recognised as a public-health concern in its own right, with residents and early-career physicians disproportionately affected. The construct of moral injury — distress arising when clinicians cannot act in accordance with their professional values because of system-level constraints — has been proposed as a complement to the classical burnout framework. Aim. To synthesise contemporary observational evidence on the epidemiology of burnout, its principal risk factors, and the role of moral injury among residents and early-career physicians, with particular attention to the Polish context. Methods. A literature review of observational studies published between 2009 and 2025 was conducted in PubMed, Scopus, and Web of Science, following the STROBE statement for reporting. Because of methodological heterogeneity, no quantitative meta-analysis was attempted; findings were integrated through qualitative narrative synthesis. Results. Burnout prevalence in this population ranged from approximately 30% to over 60%, depending on geography, specialty, and measurement instrument [11,12]. Dominant risk factors were organisational: excessive workload, administrative load, restricted professional autonomy, and impaired work–life balance. Personal attributes rarely operated as independent predictors but appeared to modify risk. Moral injury emerged as a meaningful complement to burnout, capturing the value-conflict dimension that burnout scales tend to miss [8,9]. Conclusions. Burnout and moral injury together pose a serious challenge to healthcare systems. Prevention strategies that focus exclusively on individual resilience are unlikely to succeed; the evidence points instead to structural and organisational reform [31].
- Open Access
- 31 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
LIVING ALONGSIDE DISABILITY: THE MENTAL HEALTH RISK IN SIBLING RELATIONSHIPS. A REVIEW
This review aims to examine the psychological, psychiatric, and social outcomes among siblings of pediatric patients affected by disabilities, encompassing mental, neurodevelopmental, genetic, oncological, and somatic disorders. Despite extensive research on patients, the experiences of siblings remain underexplored, although existing evidence suggests that they represent a vulnerable group at increased risk for mental health issues and decreased quality of life. A literature review was conducted focusing on studies published within the last five years to ensure accuracy and novelty. Findings indicate that siblings of affected youth frequently endure emotional distress, including anxiety, guilt, and helplessness, in addition to disturbances in family dynamics and reduced parental attention. Increased caregiving obligations often result in exhaustion, social limitations, and a perceived deprivation of childhood. Across conditions, sibling psychopathology emerged as a key mediator of reduced quality of life. While some siblings demonstrate adaptive mechanisms and develop prosocial traits, others remain at risk of persistent psychological difficulties. Severity and type of illness influence outcomes, with particularly high levels of trauma- related symptoms and, in some instances, increased physical morbidity among siblings of children with cancer, whereas genetic conditions are associated with high rates of sleep disturbances. Siblings of individuals with disabilities are significantly affected across multiple domains of functioning. The burden is multifactorial and influenced by illness severity, family context, and individual characteristics. These findings highlight the need for systematic recognition of siblings’ needs and the implementation of targeted psychosocial interventions as part of comprehensive, family-centered care.
- 31 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessLIVING ALONGSIDE DISABILITY: THE MENTAL HEALTH RISK IN SIBLING RELATIONSHIPS. A REVIEW
This review aims to examine the psychological, psychiatric, and social outcomes among siblings of pediatric patients affected by disabilities, encompassing mental, neurodevelopmental, genetic, oncological, and somatic disorders. Despite extensive research on patients, the experiences of siblings remain underexplored, although existing evidence suggests that they represent a vulnerable group at increased risk for mental health issues and decreased quality of life. A literature review was conducted focusing on studies published within the last five years to ensure accuracy and novelty. Findings indicate that siblings of affected youth frequently endure emotional distress, including anxiety, guilt, and helplessness, in addition to disturbances in family dynamics and reduced parental attention. Increased caregiving obligations often result in exhaustion, social limitations, and a perceived deprivation of childhood. Across conditions, sibling psychopathology emerged as a key mediator of reduced quality of life. While some siblings demonstrate adaptive mechanisms and develop prosocial traits, others remain at risk of persistent psychological difficulties. Severity and type of illness influence outcomes, with particularly high levels of trauma- related symptoms and, in some instances, increased physical morbidity among siblings of children with cancer, whereas genetic conditions are associated with high rates of sleep disturbances. Siblings of individuals with disabilities are significantly affected across multiple domains of functioning. The burden is multifactorial and influenced by illness severity, family context, and individual characteristics. These findings highlight the need for systematic recognition of siblings’ needs and the implementation of targeted psychosocial interventions as part of comprehensive, family-centered care.
- Open Access
- 31 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
CO-OCCURRENCE OF ASTHMA AND ANXIETY-DEPRESSIVE DISORDERS – CLINICAL IMPLICATIONS. A NARRATIVE REVIEW 2019-2026
Introduction: Asthma is one of the most common chronic diseases worldwide, and its course may be significantly influenced by psychological factors. Anxiety and depressive disorders are among the most frequent comorbidities in patients with asthma. Aim: The aim of this study was to analyze the coexistence of asthma and anxiety-depressive disorders, with particular emphasis on symptoms, pathophysiological mechanisms, and clinical implications. Materials and Methods: A narrative literature review was conducted using the PubMed database. Publications published between January 2019 and July 21, 2026 were searched using the keywords: “asthma”, “anxiety”, and “depression”. Results: Anxiety disorders were found to occur in approximately 24–35% of patients with asthma, while depression affected 12–27% of this population. The coexistence of these disorders is associated with poorer disease control, more frequent exacerbations, reduced quality of life, and diagnostic difficulties resulting from overlapping symptoms. Both biological mechanisms, including chronic inflammation and dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, as well as psychological factors, play an important role. Conclusions: Anxiety and depressive disorders constitute an important component of the clinical picture of asthma and should be routinely considered in clinical practice. A comprehensive therapeutic approach may improve disease control and patients’ quality of life.
- 31 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessCO-OCCURRENCE OF ASTHMA AND ANXIETY-DEPRESSIVE DISORDERS – CLINICAL IMPLICATIONS. A NARRATIVE REVIEW 2019-2026
Introduction: Asthma is one of the most common chronic diseases worldwide, and its course may be significantly influenced by psychological factors. Anxiety and depressive disorders are among the most frequent comorbidities in patients with asthma. Aim: The aim of this study was to analyze the coexistence of asthma and anxiety-depressive disorders, with particular emphasis on symptoms, pathophysiological mechanisms, and clinical implications. Materials and Methods: A narrative literature review was conducted using the PubMed database. Publications published between January 2019 and July 21, 2026 were searched using the keywords: “asthma”, “anxiety”, and “depression”. Results: Anxiety disorders were found to occur in approximately 24–35% of patients with asthma, while depression affected 12–27% of this population. The coexistence of these disorders is associated with poorer disease control, more frequent exacerbations, reduced quality of life, and diagnostic difficulties resulting from overlapping symptoms. Both biological mechanisms, including chronic inflammation and dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, as well as psychological factors, play an important role. Conclusions: Anxiety and depressive disorders constitute an important component of the clinical picture of asthma and should be routinely considered in clinical practice. A comprehensive therapeutic approach may improve disease control and patients’ quality of life.
- Open Access
- 27 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
ARTIFICIAL INTELLIGENCE IN MODERN MEDICINE: A COMPREHENSIVE REVIEW OF CURRENT APPLICATIONS, CHALLENGES, AND FUTURE PERSPECTIVES
Introduction: The digital transformation of healthcare is accelerating, driven by unprecedented advancements in Artificial Intelligence (AI). From large language models (LLMs) to biomolecular structure prediction, AI is redefining modern diagnostic and therapeutic standards. Aim: This review evaluates the current state of AI applications in medicine, focusing on clinical knowledge encoding, molecular drug discovery, and administrative workflow optimization, while critically addressing the technical, ethical, and systemic challenges of their institutional implementation. Materials and Methods: A structured analysis was conducted utilizing a hybrid approach that combines a multi-decade bibliometric trend perspective with a detailed synthesis of 21 landmark publications, clinical trials, and meta-analyses from high-impact journals. Results: AI demonstrates expert-level performance in medical knowledge retrieval and spatiotemporal diagnostics. AlphaFold 3 has revolutionized computational therapeutics through all-atom biomolecular interaction prediction, while ambient AI scribes significantly reduce physician burnout by automating clinical documentation workflows. However, data-driven "hallucinations" in LLMs and the inherent "black box" nature of deep learning architectures remain critical barriers to autonomous deployment. Conclusions: AI is successfully transitioning from an isolated research tool into an essential clinical "co-pilot." Achieving its full potential in Medicine 4.0 requires robust frameworks for algorithmic explainability, global dataset diversification, and a strategic synergy between machine precision and human clinical judgment.
- 27 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessARTIFICIAL INTELLIGENCE IN MODERN MEDICINE: A COMPREHENSIVE REVIEW OF CURRENT APPLICATIONS, CHALLENGES, AND FUTURE PERSPECTIVES
Introduction: The digital transformation of healthcare is accelerating, driven by unprecedented advancements in Artificial Intelligence (AI). From large language models (LLMs) to biomolecular structure prediction, AI is redefining modern diagnostic and therapeutic standards. Aim: This review evaluates the current state of AI applications in medicine, focusing on clinical knowledge encoding, molecular drug discovery, and administrative workflow optimization, while critically addressing the technical, ethical, and systemic challenges of their institutional implementation. Materials and Methods: A structured analysis was conducted utilizing a hybrid approach that combines a multi-decade bibliometric trend perspective with a detailed synthesis of 21 landmark publications, clinical trials, and meta-analyses from high-impact journals. Results: AI demonstrates expert-level performance in medical knowledge retrieval and spatiotemporal diagnostics. AlphaFold 3 has revolutionized computational therapeutics through all-atom biomolecular interaction prediction, while ambient AI scribes significantly reduce physician burnout by automating clinical documentation workflows. However, data-driven "hallucinations" in LLMs and the inherent "black box" nature of deep learning architectures remain critical barriers to autonomous deployment. Conclusions: AI is successfully transitioning from an isolated research tool into an essential clinical "co-pilot." Achieving its full potential in Medicine 4.0 requires robust frameworks for algorithmic explainability, global dataset diversification, and a strategic synergy between machine precision and human clinical judgment.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN PERIMENOPAUSAL WOMEN: THE IMPACT OF HORMONAL CHANGES ON SYMPTOM SEVERITY AND CLINICAL IMPLICATIONS – A LITERATURE REVIEW
Background: Attention-Deficit/Hyperactivity Disorder (ADHD) is increasingly recognized as a lifelong condition; however, the impact of the menopausal transition on its symptomatic trajectory remains significantly under-researched. In females, ADHD is frequently masked by compensatory mechanisms until midlife, leading to diagnostic delays. This review examines the neurobiological and clinical intersection between fluctuating ovarian steroids and ADHD pathophysiology. Methods: A narrative synthesis of 20 selected scientific sources was conducted, incorporating neuroendocrinological reviews, clinical cohort studies, neuroimaging data, and qualitative research. Results: Evidence indicates a "double whammy" effect from the convergence of neurodevelopmental dopamine deficiency and perimenopausal estrogen withdrawal. 17β-estradiol acts as a critical neuromodulator of dopaminergic and serotonergic systems, exerting neuroprotective effects on the prefrontal cortex. Its decline during perimenopause unmasks previously latent ADHD symptoms, exacerbating executive dysfunction ("brain fog"), inattention, and emotional dysregulation. Women with hormone-related mood disorders such as PMDD exhibit heightened vulnerability. Additionally, "diagnostic overshadowing" frequently occurs, whereby ADHD symptoms are misattributed to menopausal depression or anxiety. The analysis highlights the efficacy of lisdexamfetamine in mitigating cognitive deficits in this demographic. Conclusions: The menopausal transition represents a period of significant clinical vulnerability for women with ADHD. Optimizing outcomes requires individualized, interdisciplinary strategies integrating stimulant pharmacotherapy with Hormone Replacement Therapy (HRT) and gender-sensitive psychoeducation. Future longitudinal research is essential to establish standardized clinical guidelines.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
Open AccessATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN PERIMENOPAUSAL WOMEN: THE IMPACT OF HORMONAL CHANGES ON SYMPTOM SEVERITY AND CLINICAL IMPLICATIONS – A LITERATURE REVIEW
Background: Attention-Deficit/Hyperactivity Disorder (ADHD) is increasingly recognized as a lifelong condition; however, the impact of the menopausal transition on its symptomatic trajectory remains significantly under-researched. In females, ADHD is frequently masked by compensatory mechanisms until midlife, leading to diagnostic delays. This review examines the neurobiological and clinical intersection between fluctuating ovarian steroids and ADHD pathophysiology. Methods: A narrative synthesis of 20 selected scientific sources was conducted, incorporating neuroendocrinological reviews, clinical cohort studies, neuroimaging data, and qualitative research. Results: Evidence indicates a "double whammy" effect from the convergence of neurodevelopmental dopamine deficiency and perimenopausal estrogen withdrawal. 17β-estradiol acts as a critical neuromodulator of dopaminergic and serotonergic systems, exerting neuroprotective effects on the prefrontal cortex. Its decline during perimenopause unmasks previously latent ADHD symptoms, exacerbating executive dysfunction ("brain fog"), inattention, and emotional dysregulation. Women with hormone-related mood disorders such as PMDD exhibit heightened vulnerability. Additionally, "diagnostic overshadowing" frequently occurs, whereby ADHD symptoms are misattributed to menopausal depression or anxiety. The analysis highlights the efficacy of lisdexamfetamine in mitigating cognitive deficits in this demographic. Conclusions: The menopausal transition represents a period of significant clinical vulnerability for women with ADHD. Optimizing outcomes requires individualized, interdisciplinary strategies integrating stimulant pharmacotherapy with Hormone Replacement Therapy (HRT) and gender-sensitive psychoeducation. Future longitudinal research is essential to establish standardized clinical guidelines.
- Open Access
- 29 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
VITAMIN D AND RESPIRATORY TRACT INFECTIONS: A NARRATIVE REVIEW OF DEFICIENCY, SUPPLEMENTATION STRATEGIES, AND CLINICAL OUTCOMES
Vitamin D is widely recognised for its role in calcium homeostasis and skeletal health, yet its biological relevance extends beyond the musculoskeletal system to immune regulation and host defence. Over the past decade, the relationship between vitamin D status and respiratory tract infections (RTIs) has attracted increasing scientific interest, particularly in the context of the widespread prevalence of vitamin D deficiency and the global impact of the COVID-19 pandemic. This narrative review synthesises evidence on vitamin D deficiency, supplementation strategies, and respiratory clinical outcomes, drawing on randomised controlled trials, systematic reviews, meta-analyses, observational studies, and selected mechanistic publications. The reviewed literature consistently suggests that low serum 25-hydroxyvitamin D [25(OH)D] concentrations are associated with increased susceptibility to RTIs and, in many settings, with poorer respiratory outcomes. However, evidence regarding the benefits of supplementation remains heterogeneous. Earlier meta-analyses suggested modest protective effects, particularly among individuals with lower baseline vitamin D status and in studies using daily or weekly standard-dose regimens, whereas more recent large randomised trials and updated meta-analyses have reported smaller, inconsistent, or statistically non-significant overall effects. These discrepancies likely reflect variation in study population, baseline deficiency, supplementation regimen, trial duration, and outcome definition. Current evidence does not support a universal preventive or therapeutic role of vitamin D supplementation for all RTIs, but it strongly supports the importance of identifying and correcting deficiency, particularly in high-risk groups. From a wider perspective, vitamin D deficiency should also be understood as a socially patterned and potentially modifiable determinant of health, with relevance to prevention, health equity, and public health planning.
- 29 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
Open AccessVITAMIN D AND RESPIRATORY TRACT INFECTIONS: A NARRATIVE REVIEW OF DEFICIENCY, SUPPLEMENTATION STRATEGIES, AND CLINICAL OUTCOMES
Vitamin D is widely recognised for its role in calcium homeostasis and skeletal health, yet its biological relevance extends beyond the musculoskeletal system to immune regulation and host defence. Over the past decade, the relationship between vitamin D status and respiratory tract infections (RTIs) has attracted increasing scientific interest, particularly in the context of the widespread prevalence of vitamin D deficiency and the global impact of the COVID-19 pandemic. This narrative review synthesises evidence on vitamin D deficiency, supplementation strategies, and respiratory clinical outcomes, drawing on randomised controlled trials, systematic reviews, meta-analyses, observational studies, and selected mechanistic publications. The reviewed literature consistently suggests that low serum 25-hydroxyvitamin D [25(OH)D] concentrations are associated with increased susceptibility to RTIs and, in many settings, with poorer respiratory outcomes. However, evidence regarding the benefits of supplementation remains heterogeneous. Earlier meta-analyses suggested modest protective effects, particularly among individuals with lower baseline vitamin D status and in studies using daily or weekly standard-dose regimens, whereas more recent large randomised trials and updated meta-analyses have reported smaller, inconsistent, or statistically non-significant overall effects. These discrepancies likely reflect variation in study population, baseline deficiency, supplementation regimen, trial duration, and outcome definition. Current evidence does not support a universal preventive or therapeutic role of vitamin D supplementation for all RTIs, but it strongly supports the importance of identifying and correcting deficiency, particularly in high-risk groups. From a wider perspective, vitamin D deficiency should also be understood as a socially patterned and potentially modifiable determinant of health, with relevance to prevention, health equity, and public health planning.
- Open Access
- 19 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
CLINICAL APPLICATIONS OF ARTIFICIAL INTELLIGENCE IN MODERN HEMATOLOGY: DIAGNOSTIC AND PROGNOSTIC PERSPECTIVES
Artificial intelligence (AI) has recently emerged as an important tool supporting diagnostics and clinical decision-making across multiple fields of medicine, including hematology. Rapid advances in machine learning algorithms and computational data analysis have enabled the processing and interpretation of complex biomedical datasets derived from laboratory diagnostics, medical imaging, and molecular studies [1,2]. These developments are particularly relevant in hematology, where the interpretation of large volumes of morphological, immunophenotypic, and genetic data plays a crucial role in disease diagnosis and monitoring. In hematological practice, artificial intelligence has demonstrated promising applications in the automated analysis of peripheral blood smears and bone marrow aspirates, as well as in the interpretation of flow cytometry data and molecular diagnostic results [3,4]. Several studies have shown that AI-based systems can achieve high levels of sensitivity and specificity in the detection of abnormal cellular populations, including leukemic blasts, potentially improving diagnostic accuracy and reducing the time required for laboratory evaluation [5]. Despite these promising developments, the clinical implementation of artificial intelligence in hematology remains associated with several challenges, including the need for large, high-quality training datasets, external validation across different patient populations, and integration with existing laboratory information systems [6]. The aim of this article is to review the current state of knowledge regarding the use of artificial intelligence in hematology, with particular emphasis on its applications in laboratory diagnostics, microscopic image analysis, and prognostic modeling in hematological diseases.
- 19 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
Open AccessCLINICAL APPLICATIONS OF ARTIFICIAL INTELLIGENCE IN MODERN HEMATOLOGY: DIAGNOSTIC AND PROGNOSTIC PERSPECTIVES
Artificial intelligence (AI) has recently emerged as an important tool supporting diagnostics and clinical decision-making across multiple fields of medicine, including hematology. Rapid advances in machine learning algorithms and computational data analysis have enabled the processing and interpretation of complex biomedical datasets derived from laboratory diagnostics, medical imaging, and molecular studies [1,2]. These developments are particularly relevant in hematology, where the interpretation of large volumes of morphological, immunophenotypic, and genetic data plays a crucial role in disease diagnosis and monitoring. In hematological practice, artificial intelligence has demonstrated promising applications in the automated analysis of peripheral blood smears and bone marrow aspirates, as well as in the interpretation of flow cytometry data and molecular diagnostic results [3,4]. Several studies have shown that AI-based systems can achieve high levels of sensitivity and specificity in the detection of abnormal cellular populations, including leukemic blasts, potentially improving diagnostic accuracy and reducing the time required for laboratory evaluation [5]. Despite these promising developments, the clinical implementation of artificial intelligence in hematology remains associated with several challenges, including the need for large, high-quality training datasets, external validation across different patient populations, and integration with existing laboratory information systems [6]. The aim of this article is to review the current state of knowledge regarding the use of artificial intelligence in hematology, with particular emphasis on its applications in laboratory diagnostics, microscopic image analysis, and prognostic modeling in hematological diseases.
- Open Access
- 17 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
PHARMACOTHERAPY IN MUSCLE DYSMORPHIC DISORDER: CLINICAL CONSIDERATIONS AND THE LIMITS OF EXTRAPOLATING EVIDENCE FROM BODY DYSMORPHIC DISORDER
Background: Muscle dysmorphic disorder is a specifier of body dysmorphic disorder (BDD) characterized by a tenacious belief of insufficient muscularity. Although currently classified within BDD, muscle dysmorphism exhibits distinct clinical and behavioral features, constituting compulsive exercise, rigid dietary practices, and use of performance-enhancing substances. Aforementioned differences raise concerns regarding applicability of pharmacotherapeutic strategies derived from BDD studies to patients with muscle dysmorphism. The aim of the study is to critically evaluate the existing literature on pharmacotherapy in body dysmorphic disorder and assess its clinical applicability to muscle dysmorphic disorder, with considerations of diverging neurobiological, phenomenological, and behavioral distinction limiting direct generalizability. Methods: A broad literature search was conducted in three major databases: PubMed, Cochrane Library, and Google Scholar, utilizing search terms (“muscle dysmorphism” or “muscle dysmorphic disorder” or “bigorexia nervosa” or “body dysmorphic disorder”) and (“pharmacotherapy” or “treatment” or “medication” or “pharmaceutical”). References were screened for relevance, and a total of 20 studies published between 1996 and 2026 were included in the analysis. Results: This review evaluates and summarizes established pharmacological strategies used in the treatment of BDD and examines their potential relevance for muscle dysmorphic disorder. Selective serotonin reuptake inhibitors (SSRIs) remain the most consistently supported pharmacological intervention, demonstrating meaningful reductions in symptom severity across several studies. Additional treatments, including clomipramine and serotonin–noradrenaline reuptake inhibitors, have shown potential benefits in selected cases. Emerging therapeutic approaches, such as glutamatergic modulators, intranasal oxytocin, and psychedelic-assisted therapy, remain experimental. However, no clinical trials have specifically examined pharmacotherapy in muscle dysmorphic disorder. Conclusions: Pharmacological strategies developed for BDD may provide partial therapeutic benefit, important differences in clinical presentation and potential neurobiological mechanisms limit direct extrapolation to muscle dysmorphic disorder. Future research should prioritize clinically controlled randomized trials exploring targeted pharmacological treatments for this condition.
- 17 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
Open AccessPHARMACOTHERAPY IN MUSCLE DYSMORPHIC DISORDER: CLINICAL CONSIDERATIONS AND THE LIMITS OF EXTRAPOLATING EVIDENCE FROM BODY DYSMORPHIC DISORDER
Background: Muscle dysmorphic disorder is a specifier of body dysmorphic disorder (BDD) characterized by a tenacious belief of insufficient muscularity. Although currently classified within BDD, muscle dysmorphism exhibits distinct clinical and behavioral features, constituting compulsive exercise, rigid dietary practices, and use of performance-enhancing substances. Aforementioned differences raise concerns regarding applicability of pharmacotherapeutic strategies derived from BDD studies to patients with muscle dysmorphism. The aim of the study is to critically evaluate the existing literature on pharmacotherapy in body dysmorphic disorder and assess its clinical applicability to muscle dysmorphic disorder, with considerations of diverging neurobiological, phenomenological, and behavioral distinction limiting direct generalizability. Methods: A broad literature search was conducted in three major databases: PubMed, Cochrane Library, and Google Scholar, utilizing search terms (“muscle dysmorphism” or “muscle dysmorphic disorder” or “bigorexia nervosa” or “body dysmorphic disorder”) and (“pharmacotherapy” or “treatment” or “medication” or “pharmaceutical”). References were screened for relevance, and a total of 20 studies published between 1996 and 2026 were included in the analysis. Results: This review evaluates and summarizes established pharmacological strategies used in the treatment of BDD and examines their potential relevance for muscle dysmorphic disorder. Selective serotonin reuptake inhibitors (SSRIs) remain the most consistently supported pharmacological intervention, demonstrating meaningful reductions in symptom severity across several studies. Additional treatments, including clomipramine and serotonin–noradrenaline reuptake inhibitors, have shown potential benefits in selected cases. Emerging therapeutic approaches, such as glutamatergic modulators, intranasal oxytocin, and psychedelic-assisted therapy, remain experimental. However, no clinical trials have specifically examined pharmacotherapy in muscle dysmorphic disorder. Conclusions: Pharmacological strategies developed for BDD may provide partial therapeutic benefit, important differences in clinical presentation and potential neurobiological mechanisms limit direct extrapolation to muscle dysmorphic disorder. Future research should prioritize clinically controlled randomized trials exploring targeted pharmacological treatments for this condition.